Primary CMV infections are common in kidney transplant recipients after 6 months valganciclovir prophylaxis.
about
CMV: Prevention, Diagnosis and TherapyClinical utility of viral load in management of cytomegalovirus infection after solid organ transplantationDirect and Indirect Effects of Cytomegalovirus-Induced γδ T Cells after Kidney TransplantationLong-term impact of CMV infection on allografts and on patient survival in renal transplant patients with protocol biopsies.Current characteristics and outcome of cytomegalovirus infections after kidney transplantation.Delayed-onset cytomegalovirus disease coded during hospital readmission after kidney transplantation.Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipientsRisk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxisEfficacy of Extended Valganciclovir Prophylaxis in Preventing Cytomegalovirus Infection in Pediatric Kidney Transplantation.Use of leflunomide in renal transplant recipients with ganciclovir-resistant/refractory cytomegalovirus infection: a case series from the University of Chicago.Accuracy of Inpatient International Classification of Diseases, Ninth Revision, Clinical Modification Coding for Cytomegalovirus After Kidney Transplantation.Plasma IL-10 Levels to Guide Antiviral Prophylaxis Prevention of Late-Onset Cytomegalovirus Disease, in High Risk Solid Kidney and Liver Transplant RecipientsCytomegalovirus disease in African-American kidney transplant patientsPharmacoepidemiology of cytomegalovirus prophylaxis in a large retrospective cohort of kidney transplant recipients with Medicare Part D coverage.Viral surveillance and subclinical viral infection in pediatric kidney transplantation.Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis.First face composite-tissue transplant recipient successfully treated for cytomegalovirus infection with preemptive valganciclovir treatment.Easier Control of Late-Onset Cytomegalovirus Disease Following Universal Prophylaxis Through an Early Antiviral Immune Response in Donor-Positive, Recipient-Negative Kidney Transplants.Prevalence and genotype distribution of cytomegalovirus UL55 sequence in renal transplant recipients in north west of Iran.[Specific infections in organ transplantation].Two-year post-transplantation cytomegalovirus DNAemia in asymptomatic kidney transplant recipients: incidence, risk factors, and outcome.Cytomegalovirus Infection following Kidney Transplantation: a Multicenter Study of 3065 Cases.Comparison of two quantitative real-time CMV-PCR tests calibrated against the 1st WHO international standard for viral load monitoring of renal transplant patients.Perforation of the gallbladder in a patient with acute cytomegalovirus cholecystitis shortly following renal transplantation.A Markov Analysis of Screening for Late-Onset Cytomegalovirus Disease in Cytomegalovirus High-Risk Kidney Transplant Recipients.A stringent preemptive protocol reduces cytomegalovirus disease in the first 6 months after kidney transplantation.Low-Dose Valganciclovir for CMV Prophylaxis after Lung Transplantation
P2860
Q26824869-B0B6526D-B3DB-4B0C-94FF-BD7892B93A88Q26826856-13D3D75D-DB49-45C7-8D1C-3B5F3A16C1DCQ26863724-78B38137-3043-4FA0-A4E0-7EA6E0E146E3Q30278721-50AE6539-2705-4570-9B3E-291DC2210856Q33416126-2807CF92-072C-4916-B1BF-E058DE285F76Q33911369-30696D9E-5A95-4FEB-A7C5-48C9721C6F30Q33932079-77A10FB4-59A3-4056-A44D-06938FDA8CFFQ35140692-DCA4409E-3DFD-4B2F-A978-D931DA7E50DAQ35196219-57917C8F-3A47-4131-B500-086B07BC11ADQ35592509-BBF79F6C-1A8F-4101-8BC4-CB186A6D9711Q35990217-44EF5A88-BFBE-4037-BD23-41C706216B67Q36389162-84060AED-122C-4006-A71E-42AD2B241AB8Q36614140-01A95F2E-6579-4B11-85E1-123BC0D8DBCCQ36759073-80361240-F8B1-41F0-8710-1E33D5CC9C74Q38240085-67577529-9E0A-4011-87B6-C7A33C2C380CQ38334787-90A83756-845E-4ACA-979F-95EFF799DA90Q39659062-E631F158-822E-4A0D-8125-77AD6F1B3D64Q40763966-07473EAF-0E90-48FE-91FB-A163C8DE3B35Q40766494-DBB4C281-8FB9-43F4-BD1D-B00E3A167CDEQ40827667-E25D1BE4-07D4-4787-B100-9B99C09ED238Q41177320-C5C13418-6CEC-4BCE-BEA0-25CA8FA055E8Q42270109-7DE28197-F96E-4E8E-8447-B0E274ED3310Q42270373-9C12492D-A682-4ED6-9AF6-7757AB3F47D5Q43517533-387EA318-2714-4E05-8635-634CF55383B6Q48633112-70CFF8DD-4EB3-4A20-82D5-8760B835081DQ54290180-5C4970A5-ABA2-476C-8520-058CDE11DCF6Q58998329-092850F2-693D-48E5-834C-1324E618D3C7
P2860
Primary CMV infections are common in kidney transplant recipients after 6 months valganciclovir prophylaxis.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Primary CMV infections are com ...... hs valganciclovir prophylaxis.
@en
type
label
Primary CMV infections are com ...... hs valganciclovir prophylaxis.
@en
prefLabel
Primary CMV infections are com ...... hs valganciclovir prophylaxis.
@en
P2093
P1476
Primary CMV infections are com ...... hs valganciclovir prophylaxis.
@en
P2093
I Helanterä
I Lautenschlager
L Kyllönen
P Koskinen
P304
P356
10.1111/J.1600-6143.2010.03225.X
P407
P577
2010-09-01T00:00:00Z